Physician profile
Chandresh Patel
NPI 1427090638
$2,775.95
in general payments reported to CMS, 2019-2025
18 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $336 · 2021: $658 · 2022: $296 · 2023: $339 · 2024: $721 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.93 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $526.76 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $343.06 | 2019-2025 | Evenity, Prolia, Prolia |
| Impulse Dynamics (USA) INC. | $312.34 | 2024 | Optimizer |
| Abbott Laboratories | $275.82 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Novo Nordisk INC | $248.76 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $185.06 | 2019-2024 | Mounjaro |
| Boston Scientific Corporation | $145.54 | 2021-2024 | Bodyguardian |
| Pfizer INC. | $129.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.08 | 2020-2025 | Jardiance |
| Esperion Therapeutics, INC. | $120.56 | 2021 | |
| Merck Sharp & Dohme LLC | $105.90 | 2019-2023 | Steglatro, Belsomra |
| Amarin Pharma, INC. | $98.86 | 2019-2022 | |
| Sarepta Therapeutics, INC. | $85.00 | 2024 | |
| Exact Sciences Corporation | $16.77 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $15.94 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $15.73 | 2020 | |
| Sumitomo Pharma America, INC. | $14.64 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandresh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.